• 1
    Pedchenko V, Bondar O, Fogo AB et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010; 363:34354.
  • 2
    Sundaramoorthy M, Meiyappan M, Todd P, Hudson BG. Crystal structure of NC1 domains. Structural basis for type IV collagen assembly in basement membranes. J Biol Chem 2002; 277:3114253.
  • 3
    Vanacore RM, Ham AJ, Cartailler JP et al. A role for collagen IV cross-links in conferring immune privilege to the Goodpasture autoantigen: structural basis for the crypticity of B cell epitopes. J Biol Chem 2008; 283:2273748.
  • 4
    Vanacore R, Ham AJ, Voehler M et al. A Sulphilimine/Sulfilimine bond identified in collagen IV. Science 2009; 325:12304.
  • 5
    David M, Borza DB, Leinonen A, Belmont JM, Hudson BG. Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen. A molecular basis for the cryptic nature of the epitope. J Biol Chem 2001; 276:63707.
  • 6
    Borza D-B, Bondar O, Todd P et al. Quaternary organization of the Goodpasture autoantigen, the alpha 3(IV) collagen chain. Sequestration of two cryptic autoepitopes by intraprotomer interactions with the α4 and α5 NC1 domains. J Biol Chem 2002; 277:4007583.
  • 7
    Wieslander J, Langeveld J, Butkowski R, Jodlowski M, Noelken M, Hudson BG. Physical and immunochemical studies of the globular domain of type IV collagen. Cryptic properties of the Goodpasture antigen. J Biol Chem 1985; 260:856470.
  • 8
    Borza DB, Bondar O, Colon S et al. Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: novel mechanism for immune privilege and autoimmune pathogenesis. J Biol Chem 2005; 280:2714754.
  • 9
    Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999; 56:163853.
  • 10
    Zou J, Henderson L, Thomas V, Swan P, Turner AN, Phelps RG. Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes. J Am Soc Nephrol 2007; 18:7719.